Cullinan Therapeutics Reports $53.7 Million Net Loss in Q2 2026, Decreased from Previous Year

Cullinan Therapeutics, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $53.7 million, a decrease from a net loss of $70.1 million in the same period last year. For the first half of 2026, the company recorded a net loss of $103.4 million, compared to $118.6 million for the first half of 2025. The reduction in losses is attributed to a significant decrease in research and development expenses, which fell to $44.4 million in the second quarter from $61.0 million in the prior year, primarily due to a one-time upfront licensing fee of $20 million paid in 2025 for the velinotamig program.

Total operating expenses for the second quarter of 2026 were $57.3 million, down from $75.8 million in the same quarter of 2025. General and administrative expenses also decreased to $12.8 million from $14.8 million year-over-year, reflecting lower equity-based compensation and professional service costs. The company’s cash and cash equivalents stood at $78.6 million as of June 30, 2026, down from $88.3 million at the end of 2025, while total assets decreased to $363.8 million from $448.4 million.

In terms of strategic developments, Cullinan continues to advance its clinical-stage pipeline, focusing on T cell engagers for autoimmune diseases and cancer. The company is actively conducting clinical trials for several product candidates, including CLN-978 for rheumatic diseases and zipalertinib for non-small cell lung cancer. The U.S. FDA has accepted a new drug application for zipalertinib, with a target action date set for February 27, 2027. Additionally, Cullinan has entered into a sales agreement with TD Cowen to offer up to $200 million of its common stock through an at-the-market equity offering program, although no sales have been made under this program as of the reporting date.

Operationally, Cullinan has made progress in its research and development activities, with ongoing clinical trials for its product candidates. The company reported a decrease in research and development costs associated with its clinical programs, which reflects a strategic focus on optimizing resource allocation. As of June 30, 2026, Cullinan had an accumulated deficit of $691.5 million, indicating the ongoing financial challenges typical of early-stage biopharmaceutical companies. The company expects to continue incurring operating losses as it advances its clinical programs and seeks additional funding to support its operations.

Looking ahead, Cullinan anticipates that its current cash, cash equivalents, and investments will be sufficient to fund operations for at least the next twelve months. However, the company acknowledges the inherent risks and uncertainties in the biotechnology sector, including the need for additional capital to support its research and development efforts. The management remains focused on executing its strategic plans while navigating the complexities of drug development and regulatory approval processes.